For the latest information, residents of North Carolina should visit the
North Carolina Department of Health and Human Services and the Coronavirus Disease 2019 section of the Centers for Disease Control and Prevention (CDC) website.
Research contributing to discoveries associated with COVID-19 has been growing on the UNC campus over the past year. To help increase visibility of this integral research and illustrate the extensive organizational collaborations that help move UNC research forward, a team from University Libraries – Health Sciences Library analyzed the COVID-19 research output of UNC Chapel Hill (UNC-CH) researchers. Between January 2020 and April 2021, a total of 782 UNC-CH researchers have authored 579 publications.
Access the full report and supplementary data at:
Indoor mask mandate reinstated for Orange County effective August 11, 2021, at 5:00 PM.
The mandate will apply to anyone 2 years and older, regardless of vaccination status.
The mask mandate does not apply to the following individuals:
Information from OrangeCountyNC.gov
Everyone aged 5 and up is eligible to receive a vaccine!
Vaccine providers near Orange County NC:
Data from Get Your Shot (Orange County NC)
The Department of Health and Human Services has developed a plan for people to start receiving a COVID-19 booster shot beginning in the fall, with individuals being eligible starting 8 months after they received their second dose of an mRNA vaccine (either Pfizer or Moderna). There is not enough data yet for the CDC to provide a recommendation about the Johnson & Johnson vaccine.
The Food and Drug Administration (FDA) has approved one drug, remdesivir (Veklury), to treat COVID-19.
Three anti-SARS-CoV-2 monoclonal antibody products currently have Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in nonhospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization. The FDA also issued an EUA for high-titer COVID-19 convalescent plasma and only for the treatment of hospitalized patients with COVID-19 early in the disease course or hospitalized patients who have impaired immunity.
The criteria for patients to be considered for Monoclonal Antibody infusion therapy are:
To find out if you are at high risk and eligible for COVID 19 Monoclonal Antibody infusion therapy, please call the UNC COVID Help Line at 888-850-2684, between 8 a.m. and 5 p.m., 7 days a week.
UNC is also part of a large study that is working to identify additional medications to treat COVID. The project is called Rise Above COVID or the ACTIV-2 Study is investigating medicines to see if they can help adults with COVID-19 recover more quickly.
You could be eligible to participate in the study if you tested positive for Covid-19 less than 10 days before, are not in the hospital, and have Covid-19 symptoms.
The COVID-19 Treatment Guidelines Panel (the Panel) provides recommendations for using antiviral drugs to treat COVID-19 based on the available data. The following drugs have been evaluated by the Panel and not recommended, or there is not enough evidence for the Panel to make a recommendation
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion
Information on the University’s response to COVID-19, the Carolina Together Testing Program, and our COVID-19 Community Standards.
COVID-19 information as it relates to UNC Health and affiliated hospitals,
preparations, as well as tips for staying healthy
Data from NCDHHS
Links to public health alerts, advisories, and updates as well communicable disease prevention information and resources you need
Links to information on COVID-19 vaccinations,
reporting, testing, and guidance for specific groups
Links, videos, and tools for Orange County residents
CDC is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and which has now been detected in almost 70 locations internationally, including in the United States. The virus has been named “SARS-CoV-2” and the disease it causes has been named “coronavirus disease 2019” (abbreviated “COVID-19”).